Number of the records: 1  

NOVEL PSMA-SPECIFIC BINDING PROTEINS

  1. 1.
    0557143 - BTÚ 2022 RIV eng P - Patent Document
    Skerra, A. - Richter, A. - Morath, V. - Bařinka, Cyril - Ptáček, Jakub
    NOVEL PSMA-SPECIFIC BINDING PROTEINS.
    2021. Owner: Technische Universitaet Muenchen, Biotechnologický ústav AV ČR, v. v. i. Date of the patent acceptance: 14.04.2021. Patent Number: EP 3319641
    Institutional support: RVO:86652036
    Keywords : Prostate-specific membrane antigen * Anticalin * Protein engineering
    OECD category: Biochemistry and molecular biology
    https://worldwide.espacenet.com/patent/search/family/053540662/publication/EP3319641B1?q=pn%3DEP3319641B1

    The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KDof 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition, to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.
    Permanent Link: http://hdl.handle.net/11104/0331197

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.